0 CHECKOUT

Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015

  • ID: 3165004
  • March 2015
  • 42 pages
  • Global Markets Direct
1 of 4

Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015

Summary

This, ‘Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015’, provides an overview of the Chemotherapy Induced Myelosuppression’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Myelosuppression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Myelosuppression and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by READ MORE >

Note: Product cover images may vary from those shown
2 of 4

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Chemotherapy Induced Myelosuppression Overview
Therapeutics Development
Pipeline Products for Chemotherapy Induced Myelosuppression - Overview
Pipeline Products for Chemotherapy Induced Myelosuppression - Comparative Analysis
Chemotherapy Induced Myelosuppression - Therapeutics under Development by Companies
Chemotherapy Induced Myelosuppression - Therapeutics under Investigation by Universities/Institutes
Chemotherapy Induced Myelosuppression - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Chemotherapy Induced Myelosuppression - Products under Development by Companies
Chemotherapy Induced Myelosuppression - Products under Investigation by Universities/Institutes
Chemotherapy Induced Myelosuppression - Companies Involved in Therapeutics Development
Biothera, Inc.
G1 Therapeutics, Inc.
Chemotherapy Induced Myelosuppression - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
calcitriol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G-1T28 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GZ-381 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imprime PGG - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chemotherapy Induced Myelosuppression - Recent Pipeline Updates
Chemotherapy Induced Myelosuppression - Dormant Projects
Chemotherapy Induced Myelosuppression - Product Development Milestones
Featured News & Press Releases
Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG
Jun 12, 2012: Biothera Discovers Biomarker For The Cancer Drug Imprime PGG
Jun 06, 2012: Imprime PGG Binds To Adaptive Immune Cells
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Chemotherapy Induced Myelosuppression, H1 2015
Number of Products under Development for Chemotherapy Induced Myelosuppression - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Chemotherapy Induced Myelosuppression - Pipeline by Biothera, Inc., H1 2015
Chemotherapy Induced Myelosuppression - Pipeline by G1 Therapeutics, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Chemotherapy Induced Myelosuppression Therapeutics - Recent Pipeline Updates, H1 2015
Chemotherapy Induced Myelosuppression - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Chemotherapy Induced Myelosuppression, H1 2015
Number of Products under Development for Chemotherapy Induced Myelosuppression - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Biothera, Inc.
G1 Therapeutics, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)